Blueprint Medicines’ (BPMC) “Outperform” Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report released on Friday morning,RTT News reports. Wedbush currently has a $128.00 target price on the biotechnology company’s stock. Several other equities analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and […]
Wedbush reiterated their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report released on Friday morning,RTT News reports. Wedbush currently has a $128.00 target price on the biotechnology company’s stock. Several other equities analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and […]
